DiaMedica Therapeutics Inc. (DMAC)
$6.41-$0.36 (-5.33%) Today
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 922,949 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
16 Form 4 filings on record, the earliest from Jul 25, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dietrich John Pauls - Officer | Grant or award | Voting Common Shares, no par value per share | 60,200 | $0.00 | - | |
| Randall Michael Giuffre | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Richard Kuntz | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Daniel J. O'Connor | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
 Tanya Lewis | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Charles Pauling Semba | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| James T. Parsons | Grant or award | Stock Option (right to buy) | 51,189 | $0.00 | - | |
| Dietrich John Pauls - Officer | Grant or award | Stock Option (right to buy) | 380,000 | $0.00 | - | |
 Scott Kellen - Officer | Grant or award | Stock Option (right to buy) | 162,000 | $0.00 | - | |
 Julie Krop - Officer | Grant or award | Stock Option (right to buy) | 67,500 | $0.00 | - | |
| James T. Parsons | Option exercise | Common Stock | 12,000 | $2.20 | $26K | |
| James T. Parsons | Option exercise | Stock Option (right to buy) | 12,000 | $0.00 | - | |
| Julie Krop - Officer | Grant or award | Stock Option (right to buy) | 450,000 | $0.00 | - | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 293,601 | $5.91 | $1.73M | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 70,414 | $5.99 | $422K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 8,233 | $6.00 | $49K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 71,107 | $5.86 | $416K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 48,172 | $5.96 | $287K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 59,788 | $5.96 | $357K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 338,265 | $6.00 | $2.03M | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 59,648 | $6.00 | $358K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 50,772 | $6.00 | $305K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 1,542,857 | $3.50 | $5.40M | |
| Koch Thomas von - 10% Owner | Open-market purchase | Common Shares | 2,857,142 | $3.50 | $10.00M | |
| Richard Jacinto II - 10% Owner | Open-market purchase | Voting Common Shares, no par value per share | 400,000 | $3.50 | $1.40M |
DiaMedica Therapeutics Inc. (DMAC) had 10 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for DMAC runs to 16 Form 4 filings, the earliest from 2025-07-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DMAC were filed in the last 90 days. 12 purchases are on record for this company.
No insider sales of DMAC were filed in the last 90 days.
This page tracks DMAC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DMAC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
